-
-
公开(公告)号:KR1020000020032A
公开(公告)日:2000-04-15
申请号:KR1019980038442
申请日:1998-09-17
Applicant: 한국과학기술연구원
IPC: C07C321/04
Abstract: PURPOSE: Title derivatives useful as radioactive pharmaceuticals are prepared which can extend a residual time in heart, and minimize a radioactive disturbance. CONSTITUTION: 1,12-Dodecane diol is alcohol-substituted by bromic acid to give 12-bromo-dodecane-1-ol, and protected by tetrahydropyrane. Obtained dodecane, 2-ethyl-4,4-dimethyl-2-oxazoline and n-butyl lithium are reacted to give 2(R/S)-(4,4-dimethyl-2-oxazoline-2-yl)-12-tetrahydropyranyl oxy-tetradecane, and esterified with sulfuric acid to give ethyl-2(R/S)-methyl-12-hydroxytetradecaneate. Obtained tetradecaneate is protected to give ethyl-2(R/S)-methyl-14-tetra butyl dimethyl silyloxy-tetradecaneate, followed by reduction with lithium aluminum hydride to give 2(R/S)-methyl-14-t-butyl dimethyl silyloxy-tetradecane-1-ol, tosylated by tosyl chloride, and to give 3(R/S)-methyl-15-t-butyl dimethyl silyloxy-pentadecane-nitrile by substituting with sodium cyanide. Obtained nitride is treated with 1N-hydrochloric acid, hydrolyzed and mesylated to give 16-methane sulfonyl-3-methyl-pentadecanic acid. The pentadecanic acid is brominated, followed by reaction of thiourea and NaOH to give 15-mercapto-3-methyl-pentadecanic acid(formula 1).
Abstract translation: 目的:制备用作放射性药物的标题衍生物,其可以延长心脏中的残留时间,并使放射性干扰最小化。 构成:1,12-十二烷二醇被溴酸醇取代,得到12-溴 - 十二烷-1-醇,并用四氢吡喃保护。 获得的十二烷,2-乙基-4,4-二甲基-2-恶唑啉和正丁基锂反应,得到2(R / S) - (4,4-二甲基-2-恶唑啉-2-基) 四氢呋喃基氧基十四烷,并用硫酸酯化,得到乙基-2(R / S) - 甲基-12-羟基十四烷酸酯。 得到的十四烷酸乙酯得到乙基-2(R / S) - 甲基-14-四丁基二甲基甲硅烷氧基 - 十四烷酸酯,然后用氢化铝锂还原,得到2(R / S) - 甲基-14-叔丁基二甲基 甲硅烷氧基 - 十四烷-1-醇,用甲苯磺酰氯甲磺酰化,并用氰化钠代替得到3(R / S) - 甲基-15-叔丁基二甲基甲硅烷氧基 - 十五烷腈。 得到的氮化物用1N盐酸处理,水解和甲磺酰化得到16-甲磺酰基-3-甲基 - 十五烷酸。 将十五烷酸溴化,随后用硫脲和NaOH反应,得到15-巯基-3-甲基 - 十五烷酸(式1)。
-